Physician profile
David S Jenson
NPI 1629046669
$8,044.04
in general payments reported to CMS, 2019-2025
34 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $833 · 2021: $650 · 2022: $2,929 · 2023: $1,364 · 2024: $730 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,517.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $2,406.61 | 2020-2024 | |
| Paratek Pharmaceuticals, INC. | $1,458.94 | 2020-2025 | Nuzyra |
| Horizon Therapeutics Plc | $916.39 | 2019-2023 | Krystexxa |
| Smith+Nephew, INC. | $798.47 | 2022-2025 | Collagenase Santyl, Grafix Pl, Regranex |
| Stryker Corporation | $235.50 | 2022-2025 | Flexband, Augment Injectable, Ortholoc 3di |
| Zimmer Biomet Holdings, INC. | $226.13 | 2019 | |
| Melinta Therapeutics, LLC | $219.27 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $210.94 | 2019 | |
| Amgen INC. | $203.57 | 2024-2025 | Krystexxa |
| Bioventus LLC | $184.19 | 2022-2024 | Bonescalpel & Sonicone (O.R.), Exogen Ultrasound Bone Healing System, Durolane |
| Kowa Pharmaceuticals America, INC. | $183.06 | 2022-2023 | Seglentis |
| Vaporox, INC. | $153.92 | 2023 | Vht-200 Wound Treatment System |
| Osiris Therapeutics INC. | $127.61 | 2019 | |
| Wright Medical Technology, INC. | $98.24 | 2019 | |
| Axogen | $63.52 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $62.89 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $54.95 | 2021-2023 | Exparel, Zilretta, Iovera |
| Abbott Laboratories | $49.62 | 2021-2023 | Proclaim |
| Medtronic, INC. | $43.77 | 2022-2023 | Venaseal |
| Paragon 28, INC. | $37.75 | 2024 | Gorilla |
| Lifenet Health | $30.70 | 2024 | Theragenesis Wound Matrix |
| Kci USA, INC. | $30.36 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.27 | 2021 | |
| Medshape, INC. | $26.93 | 2022 | |
| Tactile Systems Technology INC | $24.12 | 2020-2021 | |
| Acera Surgical, INC. | $23.96 | 2023 | Restrata Wound Matrix |
| Triad Life Sciences INC. | $23.78 | 2022 | |
| Avanos Medical | $21.15 | 2023 | On-Q* Pump and Accessories |
| Imbed Biosciences INC. | $20.63 | 2022 | |
| Checkpoint Surgical, INC | $20.04 | 2020 | |
| Nabriva Therapeutics, Plc | $17.34 | 2020 | |
| Averitas Pharma INC. | $14.57 | 2023 | Qutenza |
| Kerecis Limited | $14.34 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Trilliant Surgical LLC. | $13.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.